|
humans |
70 |
|
female |
56 |
|
male |
51 |
|
middle aged |
48 |
|
adult |
45 |
|
aged |
38 |
|
aged, 80 and over |
29 |
|
helicobacter pylori |
27 |
|
risk factors |
25 |
|
time factors |
24 |
|
adolescent |
21 |
|
treatment outcome |
21 |
|
apoptosis |
20 |
|
gastric cancer |
20 |
|
animals |
19 |
|
blotting, western |
19 |
|
cell line, tumor |
18 |
|
china |
18 |
|
medical sciences |
17 |
|
apoptosis - drug effects |
16 |
|
hong kong - epidemiology |
16 |
|
mice |
16 |
|
prospective studies |
16 |
|
colorectal cancer |
15 |
|
follow-up studies |
15 |
|
prevalence |
15 |
|
tumor cells, cultured |
15 |
|
disease progression |
14 |
|
incidence |
14 |
|
mice, inbred balb c |
14 |
|
promoter regions, genetic |
14 |
|
cell proliferation |
13 |
|
colon cancer |
13 |
|
dna methylation |
13 |
|
hong kong |
13 |
|
anti-ulcer agents - therapeutic use |
12 |
|
case-control studies |
12 |
|
neoplasm staging |
12 |
|
transfection |
12 |
|
xaf1 |
12 |
|
acute disease |
11 |
|
age factors |
11 |
|
apoptosis - genetics |
11 |
|
double-blind method |
11 |
|
drug therapy, combination |
11 |
|
gene expression regulation, neoplastic |
11 |
|
promoter regions, genetic - genetics |
11 |
|
questionnaires |
11 |
|
severity of illness index |
11 |
|
sex factors |
11 |
|
stomach neoplasms - metabolism - pathology |
11 |
|
caspases - metabolism |
10 |
|
cell line |
10 |
|
chi-square distribution |
10 |
|
down-regulation |
10 |
|
fhl2 |
10 |
|
gene silencing |
10 |
|
helicobacter infections - drug therapy |
10 |
|
immunohistochemistry |
10 |
|
lim-homeodomain proteins |
10 |
|
mass screening - methods |
10 |
|
mice, nude |
10 |
|
mutation |
10 |
|
neoplasm proteins - genetics - metabolism |
10 |
|
omeprazole - therapeutic use |
10 |
|
predictive value of tests |
10 |
|
proportional hazards models |
10 |
|
transcription, genetic |
10 |
|
up-regulation |
10 |
|
anti-bacterial agents - therapeutic use |
9 |
|
anxiety |
9 |
|
cancer stem cell |
9 |
|
carcinogenesis |
9 |
|
cell cycle |
9 |
|
cell division - drug effects |
9 |
|
dyspepsia |
9 |
|
intracellular signaling peptides and proteins |
9 |
|
logistic models |
9 |
|
luciferases - metabolism |
9 |
|
metronidazole - therapeutic use |
9 |
|
prognosis |
9 |
|
reverse transcriptase polymerase chain reaction |
9 |
|
rna interference |
9 |
|
sensitivity and specificity |
9 |
|
stomach neoplasms - genetics - metabolism |
9 |
|
alanine transaminase - blood |
8 |
|
amoxicillin - therapeutic use |
8 |
|
anti-ulcer agents - administration & dosage |
8 |
|
breath tests |
8 |
|
china - ethnology |
8 |
|
clarithromycin - therapeutic use |
8 |
|
clinical trials as topic |
8 |
|
colonic neoplasms - genetics - metabolism |
8 |
|
colonic neoplasms - pathology |
8 |
|
colorectal neoplasms - etiology |
8 |
|
e-cadherin |
8 |
|
endoscopy, gastrointestinal |
8 |
|
epithelial cells - pathology |
8 |
|
gastroesophageal reflux disease |
8 |
|
gene expression regulation, neoplastic - drug effects |
8 |
|
homeodomain proteins - genetics - metabolism |
8 |
|
immunoprecipitation |
8 |
|
length of stay |
8 |
|
noncardiac chest pain |
8 |
|
quality of life |
8 |
|
recurrence - prevention & control |
8 |
|
retrospective studies |
8 |
|
rna, small interfering - metabolism |
8 |
|
statistics, nonparametric |
8 |
|
stomach neoplasms - genetics - metabolism - pathology |
8 |
|
transcriptional activation |
8 |
|
young adult |
8 |
|
antigen expression |
7 |
|
asian continental ancestry group |
7 |
|
biological markers - blood |
7 |
|
cancer combination chemotherapy |
7 |
|
cell cycle - drug effects |
7 |
|
cell invasion |
7 |
|
cell proliferation - drug effects |
7 |
|
cell transformation, neoplastic - genetics - metabolism - pathology |
7 |
|
china - epidemiology |
7 |
|
cost-benefit analysis |
7 |
|
dose-response relationship, drug |
7 |
|
epidemiology |
7 |
|
genotype |
7 |
|
helicobacter pylori - drug effects |
7 |
|
infant |
7 |
|
microbial sensitivity tests |
7 |
|
muscle proteins - genetics - metabolism |
7 |
|
nsaids |
7 |
|
placebos |
7 |
|
proto-oncogene proteins c-bcl-2 - metabolism |
7 |
|
proton pump inhibitor |
7 |
|
psychiatric status rating scales |
7 |
|
recurrence |
7 |
|
reproducibility of results |
7 |
|
risk assessment |
7 |
|
rna, messenger - genetics - metabolism |
7 |
|
rna, messenger - metabolism |
7 |
|
survival analysis |
7 |
|
survival rate |
7 |
|
telomerase |
7 |
|
transcription factors - genetics - metabolism |
7 |
|
two-hybrid system techniques |
7 |
|
xenograft model antitumor assays |
7 |
|
2-pyridinylmethylsulfinylbenzimidazoles |
6 |
|
adenocarcinoma - metabolism - pathology |
6 |
|
adenoma |
6 |
|
anthracenes - pharmacology |
6 |
|
anti-bacterial agents - pharmacology - therapeutic use |
6 |
|
anti-infective agents - therapeutic use |
6 |
|
anti-inflammatory agents, non-steroidal - adverse effects |
6 |
|
antibodies, bacterial - blood |
6 |
|
antineoplastic agents, hormonal - administration & dosage |
6 |
|
apoptosis - drug effects - genetics |
6 |
|
aspirin |
6 |
|
cadherins - metabolism |
6 |
|
carcinoma, hepatocellular - diagnosis - epidemiology |
6 |
|
carcinoma, hepatocellular - drug therapy - mortality |
6 |
|
carcinoma, hepatocellular - etiology |
6 |
|
ccrk |
6 |
|
cell cycle - physiology |
6 |
|
cell cycle arrest |
6 |
|
chronic disease |
6 |
|
chronic hepatitis b |
6 |
|
clarithromycin |
6 |
|
cpg islands |
6 |
|
cross-sectional studies |
6 |
|
cyclin-dependent kinases - physiology |
6 |
|
cyclooxygenase 2 - genetics - metabolism |
6 |
|
depression |
6 |
|
dinoprostone - metabolism |
6 |
|
dna, viral - blood |
6 |
|
drug resistance, viral |
6 |
|
drug therapy, combination - therapeutic use |
6 |
|
dyspepsia - diagnosis |
6 |
|
enzyme-linked immunosorbent assay |
6 |
|
gastroesophageal reflux |
6 |
|
genetic predisposition to disease |
6 |
|
hct116 cells |
6 |
|
helicobacter infections - diagnosis |
6 |
|
helicobacter infections - drug therapy - metabolism |
6 |
|
hepatitis b virus - drug effects |
6 |
|
hepatitis b virus - genetics |
6 |
|
hepatitis b, chronic - blood - complications - genetics |
6 |
|
hepatitis b, chronic - complications - drug therapy |
6 |
|
hepatocellular carcinoma |
6 |
|
hydrogen-ion concentration |
6 |
|
interferon regulatory factor-1 - metabolism |
6 |
|
intestinal metaplasia |
6 |
|
lamivudine - pharmacology - therapeutic use |
6 |
|
lamivudine - therapeutic use |
6 |
|
laryngopharyngeal reflux |
6 |
|
liver cirrhosis - complications - diagnosis |
6 |
|
liver cirrhosis - etiology |
6 |
|
liver neoplasms - diagnosis - epidemiology |
6 |
|
liver neoplasms - drug therapy - mortality |
6 |
|
liver neoplasms - etiology |
6 |
|
longitudinal studies |
6 |
|
mutation - genetics |
6 |
|
neoplasm proteins - physiology |
6 |
|
nf-kappa b - metabolism |
6 |
|
nf-κb |
6 |
|
octreotide - administration & dosage |
6 |
|
omeprazole - pharmacology - therapeutic use |
6 |
|
p53 |
6 |
|
prediction |
6 |
|
pyrazoles - pharmacology |
6 |
|
reactive oxygen species |
6 |
|
reverse transcriptase inhibitors - therapeutic use |
6 |
|
risk factor |
6 |
|
sex distribution |
6 |
|
signal transduction - drug effects |
6 |
|
sulfonamides - pharmacology |
6 |
|
telomerase - genetics - metabolism |
6 |
|
tumor markers, biological - blood |
6 |
|
tumor suppressor protein p53 - biosynthesis - genetics |
6 |
|
tumorigenesis |
6 |
|
viral core proteins - genetics |
6 |
|
2-pyridinylmethylsulfinylbenzimidazoles - therapeutic use |
5 |
|
adenocarcinoma - pathology |
5 |
|
adenoviridae - physiology |
5 |
|
age distribution |
5 |
|
amoxicillin - pharmacology - therapeutic use |
5 |
|
antimetabolites, antineoplastic - pharmacology |
5 |
|
antineoplastic agents - therapeutic use |
5 |
|
antiviral agents - therapeutic use |
5 |
|
anxiety - epidemiology |
5 |
|
apoptosis - drug effects - physiology |
5 |
|
asia - epidemiology |
5 |
|
azacitidine - analogs & derivatives - pharmacology |
5 |
|
bacterial proteins - drug effects - genetics - metabolism |
5 |
|
bcl-2-associated x protein - metabolism |
5 |
|
beta catenin - genetics - metabolism |
5 |
|
cadherins - antagonists and inhibitors - genetics |
5 |
|
cadherins - blood |
5 |
|
carcinoembryonic antigen |
5 |
|
carcinoma, hepatocellular - virology |
5 |
|
caspase 3 |
5 |
|
cell nucleus - metabolism |
5 |
|
cell transformation, viral |
5 |
|
child |
5 |
|
child, preschool |
5 |
|
chinese |
5 |
|
cholangiopancreatography, endoscopic retrograde - methods |
5 |
|
cholelithiasis - complications - diagnosis - surgery |
5 |
|
chromans - pharmacology |
5 |
|
cohort studies |
5 |
|
colloidal bismuth subcitrate |
5 |
|
colonic neoplasms - etiology - metabolism |
5 |
|
colonic neoplasms - genetics - metabolism - pathology |
5 |
|
colonic neoplasms - prevention and control |
5 |
|
colorectal neoplasms - epidemiology |
5 |
|
comorbidity |
5 |
|
coronary angiography |
5 |
|
cyclin-dependent kinase inhibitor p21 |
5 |
|
cyclooxygenase 2 inhibitors - pharmacology |
5 |
|
cyclooxygenase-2 |
5 |
|
cytochromes c - metabolism |
5 |
|
cytoplasm - metabolism |
5 |
|
dna, neoplasm - genetics |
5 |
|
dna-directed dna polymerase - genetics |
5 |
|
double-blind |
5 |
|
down-regulation - drug effects |
5 |
|
drug delivery systems |
5 |
|
drugs, chinese herbal - adverse effects |
5 |
|
endosonography |
5 |
|
enzyme inhibitors - pharmacology |
5 |
|
enzyme inhibitors - therapeutic use |
5 |
|
epithelial cells - enzymology - pathology - virology |
5 |
|
epithelial-mesenchymal transition |
5 |
|
esophageal cancer |
5 |
|
esophagoscopy |
5 |
|
esophagus - enzymology - pathology - virology |
5 |
|
fluorescent antibody technique |
5 |
|
gallstones - complications - ultrasonography |
5 |
|
gastric acidity determination |
5 |
|
gastroesophageal reflux - epidemiology - psychology |
5 |
|
gene expression profiling - methods |
5 |
|
gene expression regulation, bacterial - drug effects |
5 |
|
gene therapy |
5 |
|
gerd |
5 |
|
h(+)-k(+)-exchanging atpase - antagonists & inhibitors |
5 |
|
helicobacter pylori - chemistry - drug effects - genetics |
5 |
|
helicobacter pylori - metabolism |
5 |
|
helicobacter pylori - pathogenicity |
5 |
|
hepatitis b core antigens - genetics |
5 |
|
hepatitis b core antigens - genetics - immunology |
5 |
|
hepatitis b e antigen seroconversion |
5 |
|
hepatitis b e antigens - biosynthesis - genetics - immunology |
5 |
|
hepatitis b virus |
5 |
|
hepatitis b virus - drug effects - enzymology - genetics |
5 |
|
hepatitis b virus - drug effects - genetics |
5 |
|
hepatitis b virus - genetics - immunology |
5 |
|
hepatitis b, chronic - drug therapy |
5 |
|
hepatitis b, chronic - drug therapy - virology |
5 |
|
hepatitis b, chronic - genetics - immunology - virology |
5 |
|
homeodomain proteins - analysis - physiology |
5 |
|
homeodomain proteins - biosynthesis - genetics |
5 |
|
homeodomain proteins - metabolism |
5 |
|
homeodomain proteins - physiology |
5 |
|
hydroxamic acids - pharmacology |
5 |
|
immobilized-metal affinity chromatography |
5 |
|
immortalization |
5 |
|
immune response |
5 |
|
immunoenzyme techniques |
5 |
|
inhibitor of apoptosis proteins |
5 |
|
interferon-gamma - biosynthesis - immunology |
5 |
|
interleukin-10 - immunology |
5 |
|
interleukin-2 - immunology |
5 |
|
interleukin-4 - immunology |
5 |
|
interleukin-5 - immunology |
5 |
|
intracellular signaling peptides and proteins - antagonists & inhibitors - genetics - metabolism |
5 |
|
intracellular signaling peptides and proteins - genetics - metabolism |
5 |
|
karyotyping |
5 |
|
liver diseases - diagnosis - etiology |
5 |
|
liver diseases - etiology |
5 |
|
liver neoplasms - virology |
5 |
|
liver transplantation |
5 |
|
lung - radiography |
5 |
|
lymphocyte activation |
5 |
|
medicine, chinese traditional - adverse effects |
5 |
|
mesoderm - pathology |
5 |
|
metalloproteins - analysis - genetics |
5 |
|
mitochondria - metabolism |
5 |
|
multivariate analysis |
5 |
|
muscle proteins - analysis - physiology |
5 |
|
muscle proteins - physiology |
5 |
|
neoplasm proteins - antagonists & inhibitors - genetics - metabolism |
5 |
|
neoplastic stem cells - enzymology |
5 |
|
nickel - metabolism |
5 |
|
ofloxacin - pharmacology - therapeutic use |
5 |
|
oncogene proteins, viral - genetics - metabolism |
5 |
|
organometallic compounds - pharmacology |
5 |
|
pancreatitis - etiology - ultrasonography |
5 |
|
pancreatitis, acute necrotizing - diagnosis - etiology - surgery |
5 |
|
papillomavirus e7 proteins |
5 |
|
peptic ulcer - chemically induced - microbiology - prevention & control |
5 |
|
phosphorylation |
5 |
|
polymorphism, genetic |
5 |
|
pparγ |
5 |
|
practice guidelines as topic |
5 |
|
precancerous conditions - metabolism - pathology |
5 |
|
promoter regions (genetics) |
5 |
|
protease inhibitors |
5 |
|
protein binding |
5 |
|
protein precursors - genetics |
5 |
|
protein processing, post-translational - genetics |
5 |
|
protein synthesis inhibitors - pharmacology |
5 |
|
proteomics |
5 |
|
proteomics - methods |
5 |
|
rabeprazole |
5 |
|
repressor proteins - genetics - metabolism |
5 |
|
response elements |
5 |
|
retinoblastoma protein - metabolism |
5 |
|
rna, messenger - biosynthesis - genetics |
5 |
|
rna, small interfering - genetics |
5 |
|
serologic tests |
5 |
|
severe acute respiratory syndrome - blood - complications - radiography |
5 |
|
snail1 |
5 |
|
stomach neoplasms - genetics |
5 |
|
stomach neoplasms - pathology |
5 |
|
survival rate - trends |
5 |
|
t helper response |
5 |
|
th1 cells - immunology |
5 |
|
th2 cells - immunology |
5 |
|
thiazolidinediones - pharmacology |
5 |
|
trans-activators |
5 |
|
trans-activators - genetics - metabolism |
5 |
|
transcription factor ap-1 - genetics - metabolism |
5 |
|
transcription factors - metabolism - physiology |
5 |
|
transplantation, heterologous |
5 |
|
tumor markers, biological - metabolism |
5 |
|
tumor necrosis factor-alpha - pharmacology |
5 |
|
tumor suppressor protein p53 - genetics - metabolism |
5 |
|
tumor suppressor protein p53 - metabolism |
5 |
|
viral load |
5 |
|
x-linked inhibitor of apoptosis protein - genetics - metabolism |
5 |
|
x-linked inhibitor of apoptosis protein - genetics - physiology |
5 |
|
xiap |
5 |
|
5-asa |
4 |
|
acridine orange |
4 |
|
adenocarcinoma - blood - diagnosis |
4 |
|
adenocarcinoma - blood supply - genetics - pathology - therapy |
4 |
|
adenocarcinoma - drug therapy - enzymology - genetics |
4 |
|
adenocarcinoma - genetics - metabolism - pathology - prevention & control |
4 |
|
adenoma - complications |
4 |
|
adenomatous polyposis coli - complications - drug therapy |
4 |
|
adenomatous polyps |
4 |
|
age of onset |
4 |
|
akt kinase/protein kinase b |
4 |
|
alanine transaminase - metabolism |
4 |
|
algorithms |
4 |
|
alpha catenin |
4 |
|
amino acid motifs - drug effects - genetics |
4 |
|
angiogenesis |
4 |
|
anti-bacterial agents |
4 |
|
anti-hiv agents - therapeutic use |
4 |
|
anti-infective agents - pharmacology - therapeutic use |
4 |
|
anti-inflammatory agents, non-steroidal - pharmacology |
4 |
|
anti-ulcer agents - administration & dosage - therapeutic use |
4 |
|
anti-ulcer agents - pharmacology - therapeutic use |
4 |
|
anticarcinogenic agents - administration & dosage |
4 |
|
anticarcinogenic agents - pharmacology - therapeutic use |
4 |
|
antineoplastic agents - administration & dosage |
4 |
|
antineoplastic agents - economics - therapeutic use |
4 |
|
antineoplastic agents - pharmacology - therapeutic use |
4 |
|
antineoplastic combined chemotherapy protocols - economics - therapeutic use |
4 |
|
asia |
4 |
|
asian continental ancestry group - genetics |
4 |
|
aspartic acid - drug effects - genetics |
4 |
|
aspirin - pharmacology |
4 |
|
base sequence |
4 |
|
bcl-2-associated x protein |
4 |
|
benzoquinones - pharmacology - therapeutic use |
4 |
|
beta catenin |
4 |
|
biopsy |
4 |
|
biopsy - instrumentation - methods |
4 |
|
biopsy - methods |
4 |
|
bismuth |
4 |
|
cadherins - genetics - metabolism |
4 |
|
calcium |
4 |
|
carbon isotopes - diagnostic use |
4 |
|
carcinoma |
4 |
|
carcinoma, hepatocellular - ethnology - pathology - virology |
4 |
|
carcinoma, hepatocellular - mortality |
4 |
|
carcinoma, hepatocellular - mortality - pathology - therapy |
4 |
|
carrier state |
4 |
|
carrier state - epidemiology - immunology - microbiology |
4 |
|
caspase |
4 |
|
caspases |
4 |
|
catenin |
4 |
|
cell division - genetics |
4 |
|
cell migration |
4 |
|
cell movement - genetics |
4 |
|
cell transformation, neoplastic - genetics - metabolism |
4 |
|
cells, cultured |
4 |
|
chemoembolization, therapeutic - methods |
4 |
|
chemoprevention |
4 |
|
chemoprophylaxis |
4 |
|
chemotherapy, adjuvant |
4 |
|
chest pain - epidemiology - psychology |
4 |
|
cholangiopancreatography, endoscopic retrograde - methods - mortality |
4 |
|
cholangitis - mortality - therapy |
4 |
|
cisplatin - administration & dosage |
4 |
|
clarithromycin - pharmacology - therapeutic use |
4 |
|
clinical trial |
4 |
|
colonic neoplasms - drug therapy |
4 |
|
colonic neoplasms - drug therapy - enzymology - genetics |
4 |
|
colonic neoplasms - drug therapy - metabolism |
4 |
|
colonic neoplasms - genetics - metabolism - pathology - prevention & control |
4 |
|
colonic neoplasms - genetics - pathology |
4 |
|
colonic neoplasms - metabolism |
4 |
|
colonic neoplasms - metabolism - pathology |
4 |
|
colorectal |
4 |
|
colorectal carcinoma |
4 |
|
colorectal neoplasms - complications |
4 |
|
colorectal neoplasms - diagnosis - epidemiology - etiology - prevention & control |
4 |
|
colorectal neoplasms - drug therapy |
4 |
|
colorectal neoplasms - etiology - prevention and control |
4 |
|
complexes |
4 |
|
contrast media - administration & dosage |
4 |
|
coronary artery disease - complications |
4 |
|
cox-2 inhibitors |
4 |
|
cyclin-dependent kinase inhibitor p27 |
4 |
|
cyclooxygenase |
4 |
|
cyclooxygenase 2 |
4 |
|
cyclooxygenase 2 - chemistry - metabolism |
4 |
|
cyclooxygenase 2 inhibitors |
4 |
|
cyclooxygenase inhibitors - pharmacology |
4 |
|
cyclooxygenase inhibitors - therapeutic use |
4 |
|
cyclooxygenase-2 inhibitor sc236 |
4 |
|
cytochrome c |
4 |
|
cytoskeletal proteins - metabolism |
4 |
|
depression - epidemiology |
4 |
|
diagnosis |
4 |
|
diet - adverse effects |
4 |
|
dna, antisense - genetics |
4 |
|
dna, circular - blood - drug effects |
4 |
|
dna, viral - analysis |
4 |
|
dna, viral - blood - drug effects |
4 |
|
dna, viral - genetics |
4 |
|
dna-binding proteins |
4 |
|
dna-binding proteins - antagonists & inhibitors - genetics - metabolism |
4 |
|
drug evaluation, preclinical |
4 |
|
drug interactions |
4 |
|
drug resistance |
4 |
|
drug resistance, bacterial |
4 |
|
drug screening assays, antitumor |
4 |
|
drug therapy, combination - methods |
4 |
|
duodenal ulcer - drug therapy - microbiology - pathology |
4 |
|
duodenal ulcer - prevention & control |
4 |
|
dyspepsia - etiology |
4 |
|
dyspepsia - pathology |
4 |
|
dyspeptic patients |
4 |
|
emergencies |
4 |
|
empirical endoscopy |
4 |
|
empirical first-line eradication |
4 |
|
endoscopy - economics - methods |
4 |
|
endoscopy, digestive system - instrumentation |
4 |
|
enzyme activation |
4 |
|
enzyme activation - genetics |
4 |
|
epidemiology - trends |
4 |
|
equipment reuse |
4 |
|
flow cytometry |
4 |
|
forced expiratory volume - physiology |
4 |
|
gastric carcinoma |
4 |
|
gastroesophageal reflux - diagnosis |
4 |
|
gastroesophageal reflux - drug therapy - psychology |
4 |
|
gastroesophageal reflux - psychology |
4 |
|
gastrointestinal neoplasms - drug therapy |
4 |
|
gastrointestinal neoplasms - metabolism |
4 |
|
gene expression profiling |
4 |
|
gene expression regulation - drug effects |
4 |
|
gene expression regulation, neoplastic - physiology |
4 |
|
gene products, pol - genetics |
4 |
|
geneexpression |
4 |
|
genes, tumor suppressor |
4 |
|
glioblastoma - genetics - metabolism |
4 |
|
glioma |
4 |
|
glioma - genetics - metabolism |
4 |
|
gold (iii) |
4 |
|
graft versus host disease |
4 |
|
graft vs host disease - epidemiology - etiology - microbiology |
4 |
|
gut toxicity |
4 |
|
h pylori test-and treat |
4 |
|
health services - utilization |
4 |
|
hela cells |
4 |
|
helicobacter infections - diagnosis - ethnology |
4 |
|
helicobacter infections - diagnosis - immunology |
4 |
|
helicobacter infections - drug therapy - pathology |
4 |
|
helicobacter infections - immunology |
4 |
|
helicobacter pylori - immunology |
4 |
|
helicobacter pylori - immunology - isolation & purification |
4 |
|
helicobacter pylori - isolation & purification |
4 |
|
hepatic artery |
4 |
|
hepatitis b - complications |
4 |
|
hepatitis b - drug therapy - genetics |
4 |
|
hepatitis b - drug therapy - virology |
4 |
|
hepatitis b - virology |
4 |
|
hepatitis b antibodies - blood |
4 |
|
hepatitis b e antigens - blood |
4 |
|
hepatitis b surface antigens - analysis |
4 |
|
hepatitis b virus - classification - genetics |
4 |
|
hepatitis b virus - classification - genetics - isolation & purification - pathogenicity |
4 |
|
hepatitis b, chronic - classification - diagnosis |
4 |
|
hepatitis b, chronic - complications - ethnology - therapy |
4 |
|
hepatitis b, chronic - drug therapy - enzymology - immunology |
4 |
|
hepatitis b, chronic - drug therapy - ethnology - pathology |
4 |
|
hepatitis b, chronic - etiology |
4 |
|
hepatitis b, chronic - metabolism |
4 |
|
hepatitis b, chronic - physiopathology - virology |
4 |
|
histocompatibility |
4 |
|
human telomerase reverse transcriptase |
4 |
|
i-kappa b proteins - metabolism |
4 |
|
ifnβ |
4 |
|
in situ nick-end labeling |
4 |
|
indomethacin |
4 |
|
indomethacin - pharmacology |
4 |
|
inflammation |
4 |
|
injections, intra-arterial - methods |
4 |
|
interaction |
4 |
|
interferon regulatory factor-1 - physiology |
4 |
|
interferon-alpha - metabolism |
4 |
|
interferon-beta - metabolism - pharmacology |
4 |
|
iodized oil - administration & dosage |
4 |
|
isoleucine - genetics |
4 |
|
laryngeal diseases - psychology |
4 |
|
laryngoscopy |
4 |
|
levofloxacin |
4 |
|
liver - pathology |
4 |
|
liver cirrhosis - pathology - virology |
4 |
|
liver cirrhosis - physiopathology - virology |
4 |
|
liver cirrhosis - virology |
4 |
|
liver function tests |
4 |
|
liver neoplasms - mortality |
4 |
|
liver neoplasms - mortality - pathology - therapy |
4 |
|
macrophage migration-inhibitory factor |
4 |
|
macrophage migration-inhibitory factors - blood |
4 |
|
manometry |
4 |
|
mass screening |
4 |
|
metalloporphyrins - adverse effects - pharmacology - therapeutic use |
4 |
|
methionine - drug effects - genetics |
4 |
|
metronidazole - pharmacology - therapeutic use |
4 |
|
mice, inbred c57bl |
4 |
|
mice, transgenic |
4 |
|
microarray |
4 |
|
microtubule-associated proteins - antagonists & inhibitors - biosynthesis - genetics |
4 |
|
mitogen-activated protein kinase 8 - genetics - physiology |
4 |
|
mitogen-activated protein kinases - metabolism |
4 |
|
molecular sequence data |
4 |
|
muscle proteins - biosynthesis - deficiency - genetics |
4 |
|
muscle proteins - metabolism |
4 |
|
mutagenesis, site-directed |
4 |
|
mutation, missense - genetics |
4 |
|
neoplasm proteins |
4 |
|
neoplasm proteins - biosynthesis - deficiency - genetics |
4 |
|
neoplasm proteins - biosynthesis - genetics |
4 |
|
neoplasm proteins - genetics - physiology |
4 |
|
neoplasm recurrence, local - blood |
4 |
|
neoplasm staging - methods |
4 |
|
neovascularization, pathologic - genetics |
4 |
|
neovascularization, pathologic - genetics - therapy |
4 |
|
nf-kappa b |
4 |
|
nf-κbiα |
4 |
|
nonsteroidal antiinflammatory drugs |
4 |
|
ofloxacin - therapeutic use |
4 |
|
oligonucleotide array sequence analysis |
4 |
|
omeprazole - administration & dosage |
4 |
|
oncogenes - physiology |
4 |
|
patient acceptance of health care |
4 |
|
patient compliance |
4 |
|
peptic ulcer - chemically induced - epidemiology - prevention & control |
4 |
|
ph monitoring |
4 |
|
pharyngeal diseases - psychology |
4 |
|
phorbol esters - pharmacology |
4 |
|
physician's practice patterns |
4 |
|
poly(adp-ribose) polymerases - metabolism |
4 |
|
polymerase chain reaction |
4 |
|
ppar gamma - antagonists & inhibitors - physiology |
4 |
|
primary health care - methods |
4 |
|
proliferation |
4 |
|
protein interaction domains and motifs |
4 |
|
proto-oncogene proteins - metabolism |
4 |
|
proto-oncogene proteins c-akt - antagonists & inhibitors |
4 |
|
proto-oncogene proteins c-bcl-2 |
4 |
|
proton pump inhibitors |
4 |
|
proton pump inhibitors - therapeutic use |
4 |
|
proton pumps - antagonists & inhibitors |
4 |
|
psychology |
4 |
|
pyrazoles - therapeutic use |
4 |
|
questionnaires - standards |
4 |
|
ranitidine - analogs & derivatives |
4 |
|
rats |
4 |
|
rats, sprague-dawley |
4 |
|
recombinant proteins - metabolism |
4 |
|
registries |
4 |
|
regression analysis |
4 |
|
retreatment |
4 |
|
risk reduction behavior |
4 |
|
rna, neoplasm |
4 |
|
rna-directed dna polymerase - genetics |
4 |
|
sc-236 |
4 |
|
sc236 cyclooxygenase-2 inhibitor |
4 |
|
secular trend |
4 |
|
signal transduction |
4 |
|
specimen handling - instrumentation - methods - nursing |
4 |
|
stat1 |
4 |
|
stat1 transcription factor - metabolism |
4 |
|
stem cell transplantation |
4 |
|
stem cell transplantation - adverse effects - methods |
4 |
|
stomach neoplasms - blood - diagnosis |
4 |
|
stomach neoplasms - blood - diagnosis - mortality |
4 |
|
stomach neoplasms - blood - surgery |
4 |
|
stomach neoplasms - blood supply - genetics - pathology - therapy |
4 |
|
stomach ulcer - prevention & control |
4 |
|
stress |
4 |
|
subcellular fractions |
4 |
|
sulfonamides - therapeutic use |
4 |
|
telomerase - antagonists & inhibitors - genetics - metabolism |
4 |
|
ticlopidine - administration & dosage - analogs & derivatives |
4 |
|
trans-activators - metabolism |
4 |
|
transcription factor ap-1 - metabolism |
4 |
|
transcription factors - biosynthesis - deficiency - genetics |
4 |
|
transcription factors - metabolism |
4 |
|
transcription initiation site |
4 |
|
trend |
4 |
|
tretinoin - pharmacology |
4 |
|
tumor marker |
4 |
|
tumor markers, biological - analysis |
4 |
|
tumor suppressor proteins |
4 |
|
tyrosine - drug effects - genetics |
4 |
|
up-regulation - genetics |
4 |
|
urea - analysis |
4 |
|
valine - genetics |
4 |
|
viremia - complications |
4 |
|
virus replication |
4 |
|
vitamin d |
4 |
|
xiap-associated factor 1 |
4 |
|
5-ht3 receptor antagonist |
3 |
|
5-lipoxygenase |
3 |
|
absenteeism |
3 |
|
actins - metabolism |
3 |
|
adaptation, psychological |
3 |
|
adenocarcinoma - drug therapy - enzymology - pathology |
3 |
|
adenoma - etiology - pathology |
3 |
|
adenoviridae |
3 |
|
adenovirus |
3 |
|
administration, oral |
3 |
|
ambulatory care facilities - utilization |
3 |
|
ambulatory surgical procedures |
3 |
|
amino acid sequence |
3 |
|
amoxicillin-potassium clavulanate combination - therapeutic use |
3 |
|
amyloidosis - complications - metabolism - radiography |
3 |
|
anal canal - physiopathology |
3 |
|
analgesics, opioid - pharmacology |
3 |
|
anilides - pharmacology |
3 |
|
anorectal physiology |
3 |
|
antacids - administration & dosage - therapeutic use |
3 |
|
anti-bacterial agents - administration & dosage - therapeutic use |
3 |
|
anti-bacterial agents - adverse effects - therapeutic use |
3 |
|
anti-infective agents - administration & dosage - adverse effects - pharmacology |
3 |
|
anti-inflammatory agents - administration & dosage - pharmacology |
3 |
|
anti-inflammatory agents, non-steroidal - administration & dosage - adverse effects - therapeutic use |
3 |
|
anti-inflammatory agents, non-steroidal - therapeutic use |
3 |
|
anti-ulcer agents - adverse effects - therapeutic use |
3 |
|
antibiotic resistance |
3 |
|
antiemetic |
3 |
|
antineoplastic agents - pharmacology |
3 |
|
antineoplastic combined chemotherapy protocols - pharmacology |
3 |
|
anxiety - complications |
3 |
|
anxiety disorders - ethnology |
3 |
|
ap-1 |
3 |
|
apoptosis - physiology |
3 |
|
asian continental ancestry group - ethnology |
3 |
|
aspirin - administration & dosage |
3 |
|
aspirin - administration & dosage - pharmacology |
3 |
|
aspirin - adverse effects |
3 |
|
bar |
3 |
|
bax |
3 |
|
biliary tract diseases - therapy |
3 |
|
blood vessels - drug effects |
3 |
|
bronchiectasis - immunology - microbiology |
3 |
|
butadienes - pharmacology |
3 |
|
c-jun nh2-terminal kinase |
3 |
|
cadherins-genetics |
3 |
|
camp response element-binding protein |
3 |
|
carcinoembryonic antigen - metabolism |
3 |
|
carcinoma - metabolism |
3 |
|
carcinoma, hepatocellular - epidemiology - genetics - virology |
3 |
|
carcinoma, hepatocellular - mortality - therapy |
3 |
|
caspase 7 |
3 |
|
cd44 |
3 |
|
celecoxib |
3 |
|
cell adhesion - genetics |
3 |
|
cell aging |
3 |
|
cell cycle - genetics |
3 |
|
cell cycle proteins - biosynthesis - genetics |
3 |
|
cell cycle proteins - metabolism |
3 |
|
cell differentiation |
3 |
|
cell division - physiology |
3 |
|
cell growth processes - genetics |
3 |
|
cell shape |
3 |
|
cell transformation, neoplastic |
3 |
|
cell viability |
3 |
|
chemoembolization, therapeutic - adverse effects - methods |
3 |
|
chemotherapy |
3 |
|
chest pain |
3 |
|
chest pain - diagnosis - etiology - psychology |
3 |
|
chest pain - epidemiology |
3 |
|
cholangiopancreatography, endoscopic retrograde |
3 |
|
cholangiopancreatography, endoscopic retrograde - adverse effects - methods |
3 |
|
cholangitis - etiology |
3 |
|
cholangitis - surgery - therapy |
3 |
|
cholecystectomy - methods |
3 |
|
choledocholithiasis - complications - surgery |
3 |
|
choristoma - pathology - prevention & control |
3 |
|
ciap2 |
3 |
|
clarithromycin - administration & dosage - therapeutic use |
3 |
|
clinical criteria for same-day discharge |
3 |
|
clinical practice |
3 |
|
clone cells |
3 |
|
clopidogrel |
3 |
|
cold temperature |
3 |
|
colitis, ulcerative - etiology - pathology |
3 |
|
colon carcinoma |
3 |
|
colonic diseases, functional - ethnology - psychology |
3 |
|
colonic neoplasms - drug therapy - pathology |
3 |
|
colonic neoplasms - etiology - pathology |
3 |
|
colonoscopy |
3 |
|
colorectal neoplasia |
3 |
|
constipation |
3 |
|
constipation - complications |
3 |
|
constipation - diagnosis |
3 |
|
constipation - epidemiology - genetics |
3 |
|
constipation - epidemiology - physiopathology - psychology |
3 |
|
coping mechanism |
3 |
|
creb-binding protein - genetics - metabolism |
3 |
|
cross-over studies |
3 |
|
cyclin b - metabolism |
3 |
|
cyclin b1 |
3 |
|
cyclin-dependent kinase inhibitor p21 - metabolism |
3 |
|
cyclins - biosynthesis |
3 |
|
cyclins - biosynthesis - genetics |
3 |
|
cyclins - metabolism |
3 |
|
cyclooxygenase 2 inhibitors - adverse effects - therapeutic use |
3 |
|
cyclooxygenase inhibitors - administration & dosage - pharmacology |
3 |
|
cysteine endopeptidases - physiology |
3 |
|
cysteine proteinase inhibitors - pharmacology |
3 |
|
decompression, surgical |
3 |
|
depressive disorder - complications |
3 |
|
depressive disorder - ethnology |
3 |
|
dexamethasone |
3 |
|
dextran sulfate - toxicity |
3 |
|
dinoprostone - analysis |
3 |
|
dinoprostone - antagonists & inhibitors |
3 |
|
disease models, animal |
3 |
|
diterpenes - pharmacology |
3 |
|
dna - genetics - metabolism |
3 |
|
dna, antisense - administration & dosage - genetics |
3 |
|
drainage |
3 |
|
drug administration schedule |
3 |
|
drug synergism |
3 |
|
dyspepsia - chemically induced |
3 |
|
dyspepsia - ethnology - psychology |
3 |
|
dyspepsia - microbiology |
3 |
|
dyspepsia - physiopathology |
3 |
|
dyspnea - epidemiology |
3 |
|
efficiency |
3 |
|
electrophoretic mobility shift assay |
3 |
|
endoscopic retrograde cholangiopancreatography |
3 |
|
endoscopy, gastrointestinal - utilization |
3 |
|
endothelial growth factors - metabolism |
3 |
|
enzyme activation - drug effects |
3 |
|
enzyme activation - physiology |
3 |
|
enzyme-linked immunosorbent assay - methods - standards |
3 |
|
epidermal growth factor - pharmacology |
3 |
|
epoxy compounds |
3 |
|
esophagitis - drug therapy - ethnology |
3 |
|
european continental ancestry group - ethnology |
3 |
|
extracellular signal-regulated kinase |
3 |
|
extracellular signal-regulated map kinases - metabolism |
3 |
|
family characteristics |
3 |
|
family practice - organization & administration |
3 |
|
g2 phase - drug effects |
3 |
|
gallstones - therapy |
3 |
|
gastric mucosa - blood supply - drug effects - pathology |
3 |
|
gastric mucosa - chemistry - drug effects - pathology |
3 |
|
gastric mucosa - immunology - microbiology - pathology |
3 |
|
gastric mucosa - metabolism - microbiology |
3 |
|
gastric mucosa - metabolism - pathology |
3 |
|
gastric mucosa - pathology |
3 |
|
gastric ulcer |
3 |
|
gastritis-genetics |
3 |
|
gastro-oesophageal reflux disease |
3 |
|
gastroesophageal reflux - diagnosis - physiopathology - psychology |
3 |
|
gastroesophageal reflux - drug therapy - ethnology |
3 |
|
gastroesophageal reflux - epidemiology |
3 |
|
gastroesophageal reflux - epidemiology - therapy |
3 |
|
gastroesophageal reflux - ethnology - etiology |
3 |
|
gastroesophageal reflux - ethnology - physiopathology |
3 |
|
gastrointestinal cancers |
3 |
|
gastrointestinal neoplasms - diagnosis |
3 |
|
gastrointestinal transit |
3 |
|
gene expression |
3 |
|
gene therapy - methods |
3 |
|
genetic vectors |
3 |
|
gerbillinae |
3 |
|
glutathione transferase |
3 |
|
guideline adherence |
3 |
|
h. pylori eradication |
3 |
|
h. pylori infection |
3 |
|
health services accessibility - organization & administration |
3 |
|
health surveys |
3 |
|
helicobacter infections - complications |
3 |
|
helicobacter infections - complications - drug therapy |
3 |
|
helicobacter infections - complications - drug therapy - pathology |
3 |
|
helicobacter infections - complications - genetics - metabolism |
3 |
|
helicobacter infections - diagnosis - therapy |
3 |
|
helicobacter infections - drug therapy - ethnology |
3 |
|
helicobacter infections - drug therapy - microbiology |
3 |
|
helicobacter infections - microbiology - pathology |
3 |
|
helicobacter infections - pathology |
3 |
|
helicobacter pylori - drug effects - isolation & purification |
3 |
|
helicobacter pylori - physiology |
3 |
|
helicobacter-infections-genetics |
3 |
|
helicobacter-pylori |
3 |
|
hematologic-neoplasms-drug-therapy |
3 |
|
hepacivirus - drug effects - genetics |
3 |
|
hepacivirus - genetics - isolation and purification |
3 |
|
hepatitis b - complications - virology |
3 |
|
hepatitis b, chronic - complications - epidemiology - genetics |
3 |
|
hepatitis c - complications - virology |
3 |
|
hepatitis c, chronic - drug therapy - virology |
3 |
|
hepatitis-b-prevention-and-control |
3 |
|
hepatitis-b-virus-physiology |
3 |
|
heterotopic proliferative glands |
3 |
|
ht29 cells |
3 |
|
htert c-terminus |
3 |
|
hydrogen peroxide - pharmacology |
3 |
|
hyperplasia - prevention & control |
3 |
|
immunoglobulin g - blood |
3 |
|
indoles - pharmacology |
3 |
|
inflammation - pathology - prevention & control |
3 |
|
inhibitor of apoptosis proteins - genetics - metabolism |
3 |
|
inhibitors of apoptosis proteins |
3 |
|
intercellular signaling peptides and proteins - metabolism |
3 |
|
interferon alfa-2b - pharmacology - therapeutic use |
3 |
|
interferon-alpha - administration & dosage - adverse effects |
3 |
|
interferon-α |
3 |
|
interpersonal relations |
3 |
|
irritable bowel syndrome - ethnology - etiology |
3 |
|
isoenzymes - antagonists & inhibitors |
3 |
|
jnk inhibitor |
3 |
|
jnk mitogen-activated protein kinases |
3 |
|
jnk mitogen-activated protein kinases - antagonists & inhibitors - genetics - metabolism |
3 |
|
ki-67 antigen - biosynthesis - genetics |
3 |
|
lamivudine-therapeutic-use |
3 |
|
lansoprazole |
3 |
|
leupeptins - pharmacology |
3 |
|
ligands |
3 |
|
lipoxygenase inhibitors - pharmacology |
3 |
|
lithotripsy - methods |
3 |
|
liver neoplasms - epidemiology - genetics - virology |
3 |
|
liver neoplasms - mortality - therapy |
3 |
|
lung - pathology |
3 |
|
lung diseases - complications - metabolism - radiography |
3 |
|
lung nodules |
3 |
|
lymphokines - metabolism |
3 |
|
map kinase kinase 1 - antagonists & inhibitors - metabolism |
3 |
|
membrane proteins |
3 |
|
membrane proteins - genetics - metabolism |
3 |
|
meta-analysis |
3 |
|
metoclopramide |
3 |
|
metronidazole - administration & dosage - therapeutic use |
3 |
|
microtubule-associated proteins - genetics - metabolism |
3 |
|
mitogen-activated protein kinase 1 |
3 |
|
mitogen-activated protein kinases - antagonists & inhibitors |
3 |
|
mk-886 |
3 |
|
morphine |
3 |
|
morphine - pharmacology |
3 |
|
mucus |
3 |
|
multienzyme complexes - antagonists & inhibitors - physiology |
3 |
|
myeloperoxidase |
3 |
|
naloxone - pharmacology |
3 |
|
naproxen - administration & dosage - adverse effects - therapeutic use |
3 |
|
neoplasm proteins - metabolism |
3 |
|
neoplasm proteins - metabolism - pharmacology - therapeutic use |
3 |
|
neovascularization, pathologic - etiology |
3 |
|
new south wales - epidemiology |
3 |
|
nitriles - pharmacology |
3 |
|
occult blood |
3 |
|
odds ratio |
3 |
|
oesophagitis |
3 |
|
oligonucleotides, antisense - genetics |
3 |
|
omeprazole - administration & dosage - adverse effects - analogs & derivatives - pharmacology |
3 |
|
omeprazole - administration & dosage - analogs & derivatives |
3 |
|
omeprazole - administration & dosage - analogs & derivatives - therapeutic use |
3 |
|
omeprazole - adverse effects - therapeutic use |
3 |
|
open-access |
3 |
|
organometallic compounds - therapeutic use |
3 |
|
outcome and process assessment (health care) |
3 |
|
outpatient |
3 |
|
oxidants - pharmacology |
3 |
|
oxidative stress |
3 |
|
p300-cbp transcription factors - metabolism |
3 |
|
p53 status |
3 |
|
pancreatitis - etiology - prevention & control |
3 |
|
patient acceptance of health care - ethnology - psychology |
3 |
|
patient acceptance of health care - statistics & numerical data |
3 |
|
patient readmission |
3 |
|
pedigree |
3 |
|
peptic ulcer hemorrhage - chemically induced |
3 |
|
peptic ulcer hemorrhage - etiology - prevention & control |
3 |
|
peptides - genetics - pharmacology |
3 |
|
phenanthrenes |
3 |
|
phosphorylation - drug effects |
3 |
|
pilot projects |
3 |
|
plasmids |
3 |
|
platelet aggregation inhibitors - administration & dosage |
3 |
|
platelet aggregation inhibitors - adverse effects |
3 |
|
post-therapeutic complication |
3 |
|
postoperative complications |
3 |
|
ppar gamma - analysis - physiology |
3 |
|
precancerous conditions - epidemiology - microbiology - pathology - prevention & control |
3 |
|
precancerous conditions - genetics - metabolism - pathology |
3 |
|
professional practice |
3 |
|
promoter regions (genetics) - genetics |
3 |
|
promoter-regions-genetics-genetics |
3 |
|
prostaglandin d2 - analogs & derivatives - pharmacology |
3 |
|
prostaglandin-endoperoxide synthases |
3 |
|
proteasome endopeptidase complex |
3 |
|
protein binding - drug effects |
3 |
|
protein kinase c - antagonists & inhibitors - genetics |
3 |
|
protein kinase c-alpha |
3 |
|
proto-oncogene proteins c-jun - genetics - metabolism |
3 |
|
pyrazoles - administration & dosage - pharmacology |
3 |
|
pyrazoles - adverse effects - therapeutic use |
3 |
|
radiography, thoracic |
3 |
|
recombinant fusion proteins - pharmacology |
3 |
|
recombinant proteins |
3 |
|
rectum - physiopathology |
3 |
|
referral and consultation - organization & administration |
3 |
|
ribavirin - pharmacology - therapeutic use |
3 |
|
rna, antisense - metabolism |
3 |
|
rna, messenger - biosynthesis |
3 |
|
screening |
3 |
|
secondary amyloidosis |
3 |
|
senescence |
3 |
|
sick leave |
3 |
|
sick leave - statistics & numerical data |
3 |
|
single-blind method |
3 |
|
sjogren's syndrome |
3 |
|
sjogren's syndrome - complications |
3 |
|
smoking - adverse effects |
3 |
|
social behavior |
3 |
|
sphincterotomy, endoscopic |
3 |
|
sphincterotomy, endoscopic - methods |
3 |
|
stents |
3 |
|
stents - adverse effects |
3 |
|
stomach - drug effects - pathology |
3 |
|
stomach neoplasms - drug therapy - enzymology - pathology |
3 |
|
stomach neoplasms - enzymology - genetics - pathology - therapy |
3 |
|
stomach neoplasms - epidemiology - microbiology - pathology - prevention & control |
3 |
|
stomach neoplasms - genetics - metabolism - microbiology |
3 |
|
stomach neoplasms - genetics - metabolism - pathology - physiopathology - therapy |
3 |
|
stomach neoplasms - immunology |
3 |
|
stomach neoplasms - metabolism - microbiology - pathology |
3 |
|
stomach ulcer - complications |
3 |
|
stomach ulcer - etiology - prevention & control |
3 |
|
stress, physiological - complications |
3 |
|
stress, psychological - epidemiology - physiopathology |
3 |
|
sulfonamides - administration & dosage - pharmacology |
3 |
|
sulfonamides - adverse effects - therapeutic use |
3 |
|
survey |
3 |
|
survival |
3 |
|
symptom score |
3 |
|
telomerase - chemistry - genetics - metabolism |
3 |
|
tetradecanoylphorbol acetate - pharmacology |
3 |
|
therapy |
3 |
|
tnf-related apoptosis-inducing ligand - metabolism - pharmacology |
3 |
|
trail |
3 |
|
trans-activators - biosynthesis - genetics |
3 |
|
transcription factor ap-1 - antagonists & inhibitors |
3 |
|
transcriptional activation - drug effects |
3 |
|
transduction, genetic |
3 |
|
tumor response |
3 |
|
tumor suppressor protein p53 - biosynthesis - genetics - metabolism |
3 |
|
tumor suppressor proteins - metabolism |
3 |
|
ubiquitin-proteasome |
3 |
|
ubiquitins - metabolism |
3 |
|
ulcers |
3 |
|
unresectable hepatocellular carcinoma |
3 |
|
up-regulation - drug effects |
3 |
|
upper endoscopy |
3 |
|
vascular endothelial growth factor a |
3 |
|
vascular endothelial growth factors |
3 |
|
virus-activation-drug-effects |
3 |
|
waiting lists |
3 |
|
wound healing - drug effects |
3 |
|
x chromosome-linked iap |
3 |
|
x-linked inhibitor of apoptosis protein - analysis - antagonists & inhibitors - physiology |
3 |
|
12-hydroxy-5,8,10,14-eicosatetraenoic acid - pharmacology |
2 |
|
2-pyridinylmethylsulfinylbenzimidazoles - administration & dosage |
2 |
|
[13c]-urea breath test |
2 |
|
abdominal pain |
2 |
|
active transport, cell nucleus - drug effects |
2 |
|
acute coronary syndrome - complications - drug therapy |
2 |
|
acute coronary syndrome - drug therapy |
2 |
|
adenocarcinoma - enzymology - etiology - prevention & control |
2 |
|
adenocarcinoma - epidemiology |
2 |
|
adenocarcinoma - metabolism |
2 |
|
adenoma - etiology - prevention & control |
2 |
|
adenoviridae - genetics |
2 |
|
amino acid chloromethyl ketones - pharmacology |
2 |
|
amino terminal sequence |
2 |
|
analysis of variance |
2 |
|
angiotensin i - metabolism |
2 |
|
angiotensin ii |
2 |
|
angiotensin ii - metabolism |
2 |
|
angiotensin ii - pharmacology |
2 |
|
anti-bacterial agents - administration & dosage |
2 |
|
anti-infective agents - administration & dosage |
2 |
|
anti-inflammatory agents, non-steroidal - administration & dosage - pharmacology |
2 |
|
anti-ulcer agents - diagnostic use - therapeutic use |
2 |
|
antibiotics |
2 |
|
antibodies, bacterial - urine |
2 |
|
antibodies, monoclonal - pharmacology |
2 |
|
anticarcinogenic agents - administration & dosage - pharmacology |
2 |
|
anticarcinogenic agents - pharmacology |
2 |
|
anticoagulants - adverse effects |
2 |
|
antigen |
2 |
|
antigens, bacterial - genetics |
2 |
|
antigens, bacterial - isolation & purification |
2 |
|
antiinflammatory activity |
2 |
|
antineoplastic activity |
2 |
|
antineoplastic agents, hormonal - therapeutic use |
2 |
|
antitrichomonal agents - therapeutic use |
2 |
|
antitubercular agents - therapeutic use |
2 |
|
apoptosis regulatory proteins - drug effects |
2 |
|
apoptosis regulatory proteins - genetics |
2 |
|
arachidonate 12-lipoxygenase - biosynthesis - genetics |
2 |
|
arachidonate 15-lipoxygenase - genetics - metabolism |
2 |
|
arachidonate 5-lipoxygenase - genetics - metabolism |
2 |
|
arsenic |
2 |
|
arsenicals - pharmacology |
2 |
|
asian continental ancestry group - statistics & numerical data |
2 |
|
aspirin - administration & dosage - adverse effects |
2 |
|
aspirin - therapeutic use |
2 |
|
asthma - epidemiology - prevention & control - psychology |
2 |
|
atypical chest pain |
2 |
|
bacterial proteins - genetics |
2 |
|
barrett esophagus - epidemiology |
2 |
|
bcl-2 homologous antagonist-killer protein |
2 |
|
bcl-x protein |
2 |
|
benzimidazoles - administration & dosage |
2 |
|
benzimidazoles - adverse effects - therapeutic use |
2 |
|
bile acids and salts - pharmacology |
2 |
|
biliary pathology |
2 |
|
bismuth - adverse effects - therapeutic use |
2 |
|
bismuth - therapeutic use |
2 |
|
blood platelets - enzymology |
2 |
|
c-reactive protein - genetics - metabolism |
2 |
|
cadherins - genetics |
2 |
|
caffeic acids - pharmacology |
2 |
|
calcium-calmodulin-dependent protein kinases - genetics |
2 |
|
cancer prevention |
2 |
|
cancer therapy |
2 |
|
carbon isotopes - analysis - diagnostic use |
2 |
|
carcinoma, hepatocellular - drug therapy |
2 |
|
carcinoma, squamous cell - epidemiology |
2 |
|
carcinoma, squamous cell - metabolism |
2 |
|
cardia |
2 |
|
cardiac fibrosis |
2 |
|
carrier state - drug therapy |
2 |
|
caspase 3 - metabolism |
2 |
|
caspases - antagonists & inhibitors - biosynthesis - genetics |
2 |
|
caspases - antagonists & inhibitors - physiology |
2 |
|
cause of death |
2 |
|
cell division - drug effects - physiology |
2 |
|
cell survival - drug effects |
2 |
|
chemicals and cas registry numbers |
2 |
|
chest pain - ethnology - etiology - prevention & control |
2 |
|
chest pain - etiology |
2 |
|
chest pain - etiology - psychology |
2 |
|
cigarette smoking |
2 |
|
citric acid - administration & dosage |
2 |
|
clarithromycin - adverse effects - therapeutic use |
2 |
|
claudin-2 |
2 |
|
colitis |
2 |
|
colitis, ulcerative - chemically induced - enzymology - pathology |
2 |
|
colitis, ulcerative - complications |
2 |
|
colo-vesical fistula |
2 |
|
colonic neoplasms - diagnosis |
2 |
|
colonic neoplasms - enzymology - etiology - prevention & control |
2 |
|
colonic neoplasms - etiology - prevention & control |
2 |
|
colonic neoplasms - metabolism - prevention & control - therapy |
2 |
|
colonoscopy - utilization |
2 |
|
colonoscopy screening |
2 |
|
colorectal neoplasms - diagnosis - epidemiology |
2 |
|
colorectal neoplasms - diagnosis - ethnology |
2 |
|
combined multichannel intraluminal impedance-ph monitoring |
2 |
|
constipation - epidemiology - etiology - physiopathology |
2 |
|
contrast media |
2 |
|
coping |
2 |
|
coronary artery disease - diagnosis - epidemiology |
2 |
|
coronary disease - drug therapy |
2 |
|
cox-2 |
2 |
|
cox-2 inhibitor |
2 |
|
cpg island methylator phenotype |
2 |
|
cpg islands - genetics |
2 |
|
crohn disease - diagnosis |
2 |
|
crohn's disease |
2 |
|
crp |
2 |
|
cyclins - genetics - metabolism |
2 |
|
cyclo-oxygenase-2 |
2 |
|
cyclooxygenase 1 - deficiency - genetics - physiology |
2 |
|
cyclooxygenase 2 - deficiency - genetics - physiology |
2 |
|
cyclooxygenase 2 - physiology |
2 |
|
dextran sulfate |
2 |
|
diabetes complications |
2 |
|
diabetes mellitus |
2 |
|
diagnosis, differential |
2 |
|
diagnostic techniques, digestive system |
2 |
|
diarrhea - chemically induced |
2 |
|
dinoprostone - biosynthesis - genetics |
2 |
|
dna damage |
2 |
|
dna modification methylases |
2 |
|
dna primers |
2 |
|
dna repair enzymes |
2 |
|
dna, antisense - pharmacology |
2 |
|
dna, neoplasm - metabolism |
2 |
|
drug combinations |
2 |
|
drug resistance in microorganisms. |
2 |
|
duodenal ulcer |
2 |
|
duodenal ulcer - drug therapy - metabolism |
2 |
|
duodenal ulcer - drug therapy - microbiology |
2 |
|
duodenal ulcer - drug therapy - microbiology - prevention & control |
2 |
|
duodenal ulcer - epidemiology - microbiology - pathology |
2 |
|
duodenum - ulcers - treatment. - china |
2 |
|
duodenum - ulcers - treatment. - china - hong kong |
2 |
|
dyspepsia - complications - drug therapy - microbiology |
2 |
|
dyspepsia - drug therapy |
2 |
|
dyspepsia - drug therapy - microbiology |
2 |
|
dyspepsia - epidemiology - microbiology |
2 |
|
eating |
2 |
|
electric impedance |
2 |
|
endoscopy |
2 |
|
endoscopy, digestive system |
2 |
|
endothelial cells |
2 |
|
endothelium, vascular - cytology - metabolism |
2 |
|
enoxaparin - administration & dosage - adverse effects |
2 |
|
enoxaparin - adverse effects |
2 |
|
epidermal growth factor - isolation & purification - metabolism |
2 |
|
epigenesis, genetic |
2 |
|
epithelial cells - metabolism - microbiology - pathology |
2 |
|
eradication |
2 |
|
erosive esophagitis |
2 |
|
escherichia coli proteins - chemistry - genetics |
2 |
|
esophageal neoplasms - epidemiology |
2 |
|
esophageal neoplasms - epidemiology - microbiology - pathology |
2 |
|
esophageal neoplasms - metabolism |
2 |
|
esophageal ph monitoring |
2 |
|
esophageal ph monitoring - instrumentation |
2 |
|
esophageal stenosis - epidemiology |
2 |
|
esophagitis - drug therapy - epidemiology - physiopathology |
2 |
|
esophagitis - epidemiology - microbiology |
2 |
|
esophagitis, peptic - complications - drug therapy - prevention & control |
2 |
|
esophagitis, peptic - drug therapy |
2 |
|
esophagus - physiology |
2 |
|
evaluation studies as topic |
2 |
|
exanthema - chemically induced |
2 |
|
f-box proteins - genetics - metabolism |
2 |
|
factors affecting healing |
2 |
|
family |
2 |
|
famotidine - administration & dosage |
2 |
|
famotidine - administration & dosage - therapeutic use |
2 |
|
fasting |
2 |
|
feces - microbiology |
2 |
|
fibrinolytic agents - administration & dosage - adverse effects |
2 |
|
fibrosis - metabolism - pathology |
2 |
|
flavanones |
2 |
|
flavonoids - pharmacology |
2 |
|
functional heartburn |
2 |
|
gastric mucosa - chemistry |
2 |
|
gastric mucosa - drug effects - metabolism |
2 |
|
gastric mucosa - physiology |
2 |
|
gastric tumor |
2 |
|
gastritis |
2 |
|
gastritis - diagnosis - drug therapy - pathology |
2 |
|
gastritis - drug therapy - metabolism |
2 |
|
gastritis - enzymology - immunology - microbiology - pathology |
2 |
|
gastritis - history - microbiology |
2 |
|
gastritis - metabolism |
2 |
|
gastro-intestinal bleeding |
2 |
|
gastroenterology |
2 |
|
gastroesophageal reflux - complications - diagnosis - drug therapy |
2 |
|
gastroesophageal reflux - complications - diagnosis - drug therapy - ethnology |
2 |
|
gastroesophageal reflux - drug therapy - epidemiology - physiopathology |
2 |
|
gastrointestinal bleeding |
2 |
|
gastrointestinal hemorrhage - chemically induced |
2 |
|
gastrointestinal hemorrhage - chemically induced - epidemiology - prevention & control |
2 |
|
gastrointestinal hemorrhage - chemically induced - prevention & control |
2 |
|
gastrointestinal hemorrhage - chemically induced - prevention and control |
2 |
|
gene expression - drug effects |
2 |
|
genes, myc - physiology |
2 |
|
genes, p16 |
2 |
|
gram-negative bacterial infections - microbiology - mortality - pathology - therapy |
2 |
|
gram-positive bacterial infections - microbiology - mortality - pathology - therapy |
2 |
|
growth inhibitors - pharmacology |
2 |
|
h pylori |
2 |
|
h pylori eradication |
2 |
|
health behavior |
2 |
|
health care costs |
2 |
|
health services needs and demand |
2 |
|
health status indicators |
2 |
|
heartburn - drug therapy |
2 |
|
helicobacter infections - blood - diagnosis - microbiology |
2 |
|
helicobacter infections - complications - drug therapy - history - microbiology |
2 |
|
helicobacter infections - complications - epidemiology |
2 |
|
helicobacter infections - diagnosis - drug therapy - pathology |
2 |
|
helicobacter infections - drug therapy - epidemiology |
2 |
|
helicobacter infections - drug therapy - metabolism - pathology |
2 |
|
helicobacter infections - enzymology - immunology - microbiology - pathology |
2 |
|
helicobacter infections - epidemiology - microbiology - pathology |
2 |
|
helicobacter infections - immunology - microbiology |
2 |
|
helicobacter infections - metabolism |
2 |
|
helicobacter infections - microbiology |
2 |
|
helicobacter infections - urine |
2 |
|
helicobacter pylori - enzymology - immunology |
2 |
|
helicobacter pylori - genetics |
2 |
|
helicobacter pylori infections - china - hong kong. |
2 |
|
helicobacter pylori infections - china. |
2 |
|
helicobacter pylori infections - treatment |
2 |
|
heme oxygenase (decyclizing) - biosynthesis - genetics - immunology - physiology |
2 |
|
heme oxygenase-1 |
2 |
|
hepatitis b - drug therapy |
2 |
|
hepatitis b e antigens - analysis |
2 |
|
histamine h2 antagonists - administration & dosage |
2 |
|
human gastric cancer cells |
2 |
|
hypermethylation |
2 |
|
hypertension |
2 |
|
hypertension - metabolism - pathology - physiopathology |
2 |
|
i-kappa b kinase |
2 |
|
i-kappa b proteins - genetics - metabolism |
2 |
|
imidazoles - pharmacology |
2 |
|
immunoassay |
2 |
|
immunochemistry |
2 |
|
immunochromatography |
2 |
|
immunologic tests - methods |
2 |
|
in vivo |
2 |
|
inducible nitric oxide synthase |
2 |
|
infant, newborn |
2 |
|
interleukin-1 - pharmacology |
2 |
|
interleukin-1β |
2 |
|
interleukin-6 |
2 |
|
interleukin-6 - blood |
2 |
|
intervention studies |
2 |
|
intestinal fistula - diagnosis - drug therapy - microbiology |
2 |
|
intestinal perforation - etiology - prevention & control |
2 |
|
intestinal tuberculosis |
2 |
|
ischemic heart disease |
2 |
|
isoenzymes - antagonists & inhibitors - metabolism |
2 |
|
isoenzymes - drug effects |
2 |
|
isoenzymes - genetics - metabolism |
2 |
|
jagged1 |
2 |
|
lamivudine - adverse effects - therapeutic use |
2 |
|
leukotriene b4 - metabolism |
2 |
|
likelihood functions |
2 |
|
linoleic acids - pharmacology |
2 |
|
lipoxygenase inhibitors - therapeutic use |
2 |
|
liver abscess - microbiology - mortality - pathology - therapy |
2 |
|
liver neoplasms - drug therapy |
2 |
|
luminescent measurements |
2 |
|
lysine - metabolism |
2 |
|
macrophage migration-inhibitory factors - biosynthesis |
2 |
|
macrophage migration-inhibitory factors - genetics - metabolism |
2 |
|
macrophage migration-inhibitory factors - immunology - metabolism |
2 |
|
macrophages - immunology |
2 |
|
magnetic resonance spectroscopy |
2 |
|
malignancy |
2 |
|
medical history taking |
2 |
|
membrane proteins - biosynthesis - genetics |
2 |
|
membrane proteins - metabolism |
2 |
|
metabolic syndrome x |
2 |
|
metalloporphyrins - pharmacology |
2 |
|
metaplasia |
2 |
|
methylation |
2 |
|
metronidazole |
2 |
|
metronidazole - administration & dosage |
2 |
|
metronidazole - adverse effects - therapeutic use |
2 |
|
metronidazole susceptibility |
2 |
|
mif |
2 |
|
mitogen-activated protein kinase |
2 |
|
mitogen-activated protein kinase 1 - metabolism |
2 |
|
mitogen-activated protein-erk kinase |
2 |
|
models, biological |
2 |
|
monocytes - cytology - microbiology |
2 |
|
multichannel intraluminal impedance, esophageal |
2 |
|
muscle proteins |
2 |
|
myocardial ischemia - drug therapy |
2 |
|
myocardium - metabolism - pathology |
2 |
|
neoplasm proteins - antagonists & inhibitors |
2 |
|
neoplasm proteins - genetics - physiology - therapeutic use |
2 |
|
neoplasms, experimental - genetics - metabolism - pathology |
2 |
|
neovascularization, pathologic - prevention & control |
2 |
|
neovascularization, physiologic - physiology |
2 |
|
nf-kappa b - antagonists & inhibitors - metabolism |
2 |
|
nitric oxide synthase - antagonists & inhibitors |
2 |
|
nitric oxide synthase type ii |
2 |
|
nmr spectroscopy |
2 |
|
non-erosive reflux disease |
2 |
|
non-fasting |
2 |
|
non-ulcer dyspepsia |
2 |
|
nonsteroidal anti-inflammatory agents. |
2 |
|
notch signaling |
2 |
|
octreotide - therapeutic use |
2 |
|
ofloxacin - administration & dosage |
2 |
|
oligonucleotides, antisense - pharmacology |
2 |
|
omeprazole - administration & dosage - therapeutic use |
2 |
|
omeprazole - adverse effects - analogs & derivatives - therapeutic use |
2 |
|
omeprazole - analogs & derivatives |
2 |
|
omeprazole - analogs & derivatives - therapeutic use |
2 |
|
organometallic compounds |
2 |
|
oxides - pharmacology |
2 |
|
p38 |
2 |
|
p38 mitogen-activated protein kinases |
2 |
|
p65 (rela) and gastric cancer |
2 |
|
pai |
2 |
|
patient education as topic |
2 |
|
pcdh10 |
2 |
|
penicillins - therapeutic use |
2 |
|
peptic ulcer |
2 |
|
peptic ulcer - chemically induced - drug therapy |
2 |
|
peptic ulcer - diagnosis - drug therapy - pathology |
2 |
|
peptic ulcer - epidemiology - microbiology |
2 |
|
peptic ulcer - history - microbiology |
2 |
|
peptic ulcer - microbiology |
2 |
|
peptic ulcer disease |
2 |
|
peptic ulcers |
2 |
|
peptide fragments - biosynthesis - genetics - physiology |
2 |
|
peroxidase - metabolism |
2 |
|
physician's role |
2 |
|
platelet aggregation - drug effects |
2 |
|
platelet aggregation inhibitors - administration & dosage - adverse effects |
2 |
|
platelet aggregation inhibitors - therapeutic use |
2 |
|
poly(adp-ribose) polymerases - biosynthesis - genetics |
2 |
|
ppar gamma - antagonists & inhibitors |
2 |
|
precancerous conditions - epidemiology - microbiology - pathology |
2 |
|
precipitating factors |
2 |
|
prostaglandin-endoperoxide synthases - drug effects |
2 |
|
prostaglandin-endoperoxide synthases - drug effects - genetics - metabolism |
2 |
|
prostaglandin-endoperoxide synthases - genetics - metabolism |
2 |
|
prostaglandins - pharmacology |
2 |
|
protein kinase c |
2 |
|
protein kinase c - antagonists & inhibitors - metabolism |
2 |
|
protein processing, post-translational - drug effects |
2 |
|
protein-serine-threonine kinases - metabolism |
2 |
|
proto-oncogene proteins - biosynthesis - genetics |
2 |
|
proto-oncogene proteins c-bcl-2 - biosynthesis - genetics |
2 |
|
proto-oncogene proteins c-bcl-2 - physiology |
2 |
|
proto-oncogene proteins c-myc - metabolism |
2 |
|
proton pump inhibitors - adverse effects |
2 |
|
proton pump inhibitors - diagnostic use - therapeutic use |
2 |
|
proton-translocating atpases - antagonists & inhibitors |
2 |
|
psychosocial factors |
2 |
|
pyloric antrum - metabolism - pathology |
2 |
|
pyloric antrum - pathology |
2 |
|
pyogenic liver abscess |
2 |
|
pyridines - pharmacology |
2 |
|
randomized controlled trials as topic |
2 |
|
ranitidine - adverse effects - analogs & derivatives - therapeutic use |
2 |
|
ranitidine - analogs & derivatives - therapeutic use |
2 |
|
rapid stool test |
2 |
|
rapid urease test |
2 |
|
reactive oxygen species - metabolism |
2 |
|
reagent kits, diagnostic |
2 |
|
reagent strips |
2 |
|
receptor, epidermal growth factor - isolation & purification - metabolism |
2 |
|
receptor, tie-1 - metabolism |
2 |
|
receptors, prostaglandin e - metabolism |
2 |
|
reference values |
2 |
|
regional health planning - trends |
2 |
|
research design |
2 |
|
resonance assignment |
2 |
|
resource implication |
2 |
|
rheumatic diseases - complications |
2 |
|
rifabutin - administration & dosage |
2 |
|
risk factors for mortality |
2 |
|
rna, messenger - analysis |
2 |
|
rna, messenger - genetics |
2 |
|
rosiglitazone |
2 |
|
signal transduction - physiology |
2 |
|
smoke - adverse effects |
2 |
|
smoking |
2 |
|
social support |
2 |
|
socioeconomic factors |
2 |
|
stomach - cancer - china. |
2 |
|
stomach - cancer - prevention. |
2 |
|
stomach - microbiology - pathology |
2 |
|
stomach - pathology |
2 |
|
stomach - physiology |
2 |
|
stomach neoplasms - diagnosis - mortality - pathology |
2 |
|
stomach neoplasms - enzymology - pathology |
2 |
|
stomach neoplasms - epidemiology - microbiology - pathology |
2 |
|
stomach neoplasms - epidemiology - microbiology - prevention & control |
2 |
|
stomach neoplasms - history - microbiology |
2 |
|
stomach neoplasms - metabolism |
2 |
|
stomach ulcer - drug therapy - microbiology - pathology |
2 |
|
stomach ulcer - epidemiology - microbiology - pathology |
2 |
|
stress, psychological - psychology |
2 |
|
sucralfate - adverse effects - therapeutic use |
2 |
|
tablets |
2 |
|
targeting |
2 |
|
telomerase - biosynthesis - genetics - metabolism - physiology |
2 |
|
telomere - physiology |
2 |
|
terminology as topic |
2 |
|
test meal |
2 |
|
tetracycline - therapeutic use |
2 |
|
tgf-β/smads |
2 |
|
ticlopidine - administration & dosage - adverse effects - analogs & derivatives |
2 |
|
ticlopidine - adverse effects - analogs & derivatives |
2 |
|
ticlopidine - adverse effects - analogs and derivatives |
2 |
|
ticlopidine - analogs & derivatives - therapeutic use |
2 |
|
time trend |
2 |
|
tnf-related apoptosis-inducing ligand - pharmacology - physiology - therapeutic use |
2 |
|
tobacco |
2 |
|
tomography, x-ray computed |
2 |
|
transcription factor rela |
2 |
|
transcription, genetic - drug effects |
2 |
|
trinitrobenzenesulfonic acid |
2 |
|
tuberculosis, gastrointestinal - diagnosis - drug therapy |
2 |
|
tumor cells, cultured - drug effects - enzymology - metabolism |
2 |
|
tumor necrosis factor-related apoptosis-inducing ligand (trail) |
2 |
|
tumor suppressor protein p14arf - genetics |
2 |
|
tumor suppressor protein p53 - biosynthesis |
2 |
|
tumor-suppressor gene |
2 |
|
ubiquitin - metabolism |
2 |
|
ubiquitin-associated (uba) domain |
2 |
|
up-regulation - physiology |
2 |
|
urea - administration & dosage - analysis |
2 |
|
urea - analysis - diagnostic use |
2 |
|
urea - metabolism |
2 |
|
urease - analysis |
2 |
|
urease - metabolism |
2 |
|
urease reagent strip |
2 |
|
x-linked inhibitor of apoptosis protein (xiap) |
2 |
|
x-linked inhibitor of apoptosis protein - chemistry - metabolism |
2 |
|
x-linked inhibitor of apoptosis protein - metabolism |
2 |
|
xenograft tumors |
2 |
|
xiap-associated factor 1 (xaf1) |
2 |
|
2,4,6-trinitrobenzene sulfonic acid |
1 |
|
acetamides - pharmacology |
1 |
|
acetophenones - pharmacology |
1 |
|
acid regurgitation |
1 |
|
acid-related disorders |
1 |
|
acute-phase proteins |
1 |
|
adenocarcinoma - ethnology - pathology - surgery |
1 |
|
adenocarcinoma - genetics - microbiology - ultrastructure |
1 |
|
adenoma - epidemiology - pathology |
1 |
|
adenoma - pathology |
1 |
|
adverse effects |
1 |
|
alkaloids |
1 |
|
alleles |
1 |
|
alpha 1-antitrypsin - metabolism |
1 |
|
amino acid isomerases - genetics |
1 |
|
amoxicillin |
1 |
|
amoxicillin - administration & dosage - therapeutic use |
1 |
|
amoxicillin - adverse effects - therapeutic use |
1 |
|
amoxycillin |
1 |
|
anemia, pernicious - drug therapy |
1 |
|
antacids - therapeutic use |
1 |
|
anti-bacterial agents - pharmacology |
1 |
|
anti-infective agents, local - administration & dosage - therapeutic use |
1 |
|
anti-inflammatory agents, non-steroidal - administration & dosage - adverse effects |
1 |
|
anti-inflammatory agents, non-steroidal - adverse effects - therapeutic use |
1 |
|
anti-inflammatory agents, non-steroidal - toxicity |
1 |
|
anti-ulcer agents - diagnostic use |
1 |
|
antibodies - analysis |
1 |
|
antibodies, bacterial - analysis |
1 |
|
anticarcinogenic agents - therapeutic use |
1 |
|
antigens, bacterial |
1 |
|
antigens, bacterial - immunology |
1 |
|
antigens, cd |
1 |
|
antigens, differentiation - genetics |
1 |
|
antigens, differentiation, b-lymphocyte - immunology - metabolism |
1 |
|
antiproliferation |
1 |
|
antisense elements (genetics) - pharmacology |
1 |
|
antralisation |
1 |
|
antralization |
1 |
|
apolipoprotein a-i - metabolism |
1 |
|
aprotinin - pharmacology |
1 |
|
arginine vasopressin - therapeutic use |
1 |
|
asia, southeastern - epidemiology |
1 |
|
aspirin - adverse effects - pharmacology - therapeutic use |
1 |
|
asthma |
1 |
|
asthma - microbiology - physiopathology |
1 |
|
atrophic gastritis |
1 |
|
bacterial outer membrane proteins - genetics |
1 |
|
bacterial proteins - analysis |
1 |
|
bacterial proteins - genetics - immunology |
1 |
|
bacterial proteins - genetics - metabolism |
1 |
|
bacterial proteins - immunology |
1 |
|
barrett esophagus - diagnosis - epidemiology |
1 |
|
barrett's disease |
1 |
|
bcl-2 |
1 |
|
bcl-2 homologous antagonist-killer protein - metabolism |
1 |
|
benzimidazoles - administration & dosage - therapeutic use |
1 |
|
benzophenanthridines |
1 |
|
benzopyrans - pharmacology |
1 |
|
benzyl compounds - pharmacology |
1 |
|
biological markers - metabolism |
1 |
|
biomarkers |
1 |
|
bistratene a |
1 |
|
blotting, northern |
1 |
|
breath tests - methods |
1 |
|
bronchiectasis |
1 |
|
bronchiectasis - complications - diagnosis |
1 |
|
c-myc |
1 |
|
caga |
1 |
|
calcium - analysis |
1 |
|
calcium channels, l-type - analysis |
1 |
|
calpain - antagonists & inhibitors |
1 |
|
capsaicin |
1 |
|
capsaicin - pharmacology |
1 |
|
capsule endoscopy - methods - standards |
1 |
|
carcinoma, hepatocellular - complications - pathology |
1 |
|
cardiology |
1 |
|
cardiovascular diseases |
1 |
|
cardiovascular diseases - chemically induced |
1 |
|
caspase-3 |
1 |
|
caspases - antagonists & inhibitors - metabolism - physiology |
1 |
|
caspases - genetics - metabolism |
1 |
|
cdx2 |
1 |
|
cell differentiation - immunology |
1 |
|
cell division - drug effects - genetics |
1 |
|
cell nucleus - pathology |
1 |
|
cell transformation, neoplastic - pathology |
1 |
|
chest pain - diagnosis - epidemiology - etiology - therapy |
1 |
|
chest pain - diagnosis - etiology |
1 |
|
chest pain - drug therapy - etiology - physiopathology |
1 |
|
chest pain - epidemiology - etiology |
1 |
|
chest pain - epidemiology - etiology - therapy |
1 |
|
chest pain - etiology - therapy |
1 |
|
cigarette smoke |
1 |
|
clinical practice pattern |
1 |
|
clinical trials as topic - statistics & numerical data |
1 |
|
colitis - enzymology - etiology - prevention & control |
1 |
|
colitis, ulcerative - genetics |
1 |
|
colo 205 |
1 |
|
colon - drug effects - metabolism - pathology |
1 |
|
colon, sigmoid - pathology |
1 |
|
colonic neoplasms - chemistry - metabolism - pathology |
1 |
|
colonic polyps |
1 |
|
colonic polyps - diagnosis - epidemiology |
1 |
|
colonic polyps - pathology |
1 |
|
colonic polyps - radiography |
1 |
|
colonocytes |
1 |
|
colonography, computed tomographic |
1 |
|
colorectal neoplasms |
1 |
|
colorectal neoplasms - diagnosis |
1 |
|
colorectal neoplasms - epidemiology - pathology |
1 |
|
colorectal neoplasms - epidemiology - prevention & control |
1 |
|
colorectal neoplasms - pathology |
1 |
|
colorectal neoplasms - radiography |
1 |
|
complementary therapies - methods |
1 |
|
computed tomography |
1 |
|
consensus |
1 |
|
consensus development conferences as topic |
1 |
|
consistent inhibition |
1 |
|
constipation - drug therapy |
1 |
|
conventional colonoscopy |
1 |
|
coronary disease - therapy |
1 |
|
ctla-4 |
1 |
|
ctla-4 antigen |
1 |
|
cyclins - biosynthesis - physiology |
1 |
|
cyclooxygenase 1 |
1 |
|
cyclooxygenase inhibitor |
1 |
|
cyclooxygenase inhibitors - pharmacology - therapeutic use |
1 |
|
cyclooxygenase inhibitors - toxicity |
1 |
|
cyp4502c19 genetic polymorphism |
1 |
|
cysteine endopeptidases - drug effects - metabolism |
1 |
|
cysteine protease |
1 |
|
cytotoxin-associated gene a |
1 |
|
cytotoxin-associated gene product a |
1 |
|
cytotoxins - genetics - immunology |
1 |
|
data collection |
1 |
|
definition |
1 |
|
developing countries |
1 |
|
diet |
1 |
|
diet surveys |
1 |
|
dietary fats |
1 |
|
dietary supplements |
1 |
|
dinoprostone - analysis - metabolism |
1 |
|
dipeptides - pharmacology |
1 |
|
dna - biosynthesis |
1 |
|
dna fragmentation - drug effects |
1 |
|
dna fragmentation - drug effects - genetics |
1 |
|
dna mutational analysis |
1 |
|
dna transposable elements - genetics |
1 |
|
dna, complementary - pharmacology |
1 |
|
dna, neoplasm - analysis |
1 |
|
down-regulation - drug effects - physiology |
1 |
|
drug resistance, microbial - genetics |
1 |
|
drug resistance, multiple - genetics |
1 |
|
drug resistance, multiple, bacterial |
1 |
|
drug therapy, combination - pharmacology - therapeutic use |
1 |
|
duodenal ulcer - complications |
1 |
|
duodenal ulcer - complications - drug therapy |
1 |
|
duodenal ulcer - complications - drug therapy - microbiology |
1 |
|
duodenal ulcer - complications - drug therapy - pathology |
1 |
|
duodenal ulcer - drug therapy |
1 |
|
duodenal ulcer - drug therapy - epidemiology - microbiology |
1 |
|
duodenal ulcer - epidemiology - etiology |
1 |
|
duodenal ulcer - epidemiology - microbiology |
1 |
|
duodenal ulcer - ethnology - microbiology |
1 |
|
duodenal ulcer - microbiology |
1 |
|
dyspepsia - diagnosis - immunology - microbiology |
1 |
|
dyspepsia - diagnosis - microbiology |
1 |
|
dyspepsia - drug therapy - epidemiology - etiology |
1 |
|
dyspepsia - drug therapy - microbiology - pathology |
1 |
|
dyspepsia - ethnology - microbiology |
1 |
|
dyspepsia - metabolism - microbiology - pathology |
1 |
|
dyspepsia - microbiology - therapy |
1 |
|
dyspepsia/drug therapy |
1 |
|
egf |
1 |
|
electrophoresis, polyacrylamide gel - methods |
1 |
|
endoscopy, gastrointestinal - adverse effects |
1 |
|
endothelin-1 |
1 |
|
enzyme inhibitors - administration & dosage - therapeutic use |
1 |
|
epidemiologic research design |
1 |
|
epidermal growth factor - blood - metabolism - pharmacology |
1 |
|
epithelial cells - drug effects - pathology |
1 |
|
epithelial cells - physiology |
1 |
|
eradication therapy |
1 |
|
esomeprazole |
1 |
|
esophageal and gastric varices - drug therapy - physiopathology - ultrasonography |
1 |
|
esophageal diseases - etiology |
1 |
|
esophageal motility disorders - complications - epidemiology - therapy |
1 |
|
esophageal neoplasms - ethnology - pathology - surgery |
1 |
|
esophageal perforation - chemically induced - pathology |
1 |
|
esophageal ph monitoring - standards |
1 |
|
esophageal sphincter, lower - physiopathology |
1 |
|
esophagitis |
1 |
|
esophagitis - drug therapy |
1 |
|
esophagitis, peptic - diagnosis |
1 |
|
esophagitis, peptic - ethnology - physiopathology |
1 |
|
esophagogastric junction - pathology - surgery |
1 |
|
esophagoscopy - methods |
1 |
|
esophagus |
1 |
|
esophagus - metabolism - physiopathology |
1 |
|
esophagus - physiopathology |
1 |
|
ethanol |
1 |
|
ethnic groups |
1 |
|
ethnicity |
1 |
|
europe |
1 |
|
european continental ancestry group - statistics & numerical data |
1 |
|
evidence-based medicine |
1 |
|
evolution, molecular |
1 |
|
expression |
1 |
|
eye proteins - analysis |
1 |
|
far east |
1 |
|
far east - epidemiology |
1 |
|
fatal outcome |
1 |
|
ferrous compounds - adverse effects - therapeutic use |
1 |
|
fluorescent antibody technique, indirect |
1 |
|
forecasting |
1 |
|
freezing |
1 |
|
furazolidone - administration & dosage - therapeutic use |
1 |
|
gastric adenocarcinoma |
1 |
|
gastric epithelium |
1 |
|
gastric fundus - pathology |
1 |
|
gastric malt lymphoma |
1 |
|
gastric mucosa - chemistry - microbiology |
1 |
|
gastric mucosa - chemistry - pathology |
1 |
|
gastric mucosa - drug effects - metabolism - pathology |
1 |
|
gastric mucosa - drug effects - microbiology - pathology |
1 |
|
gastric mucosa - enzymology - pathology - physiopathology |
1 |
|
gastric mucosa - microbiology |
1 |
|
gastric mucosa - microbiology - pathology |
1 |
|
gastric ulceration |
1 |
|
gastritis - complications - pathology |
1 |
|
gastritis - drug therapy - microbiology - pathology |
1 |
|
gastritis - etiology - immunology - metabolism |
1 |
|
gastritis - immunology - microbiology |
1 |
|
gastritis - metabolism - microbiology |
1 |
|
gastritis - pathology |
1 |
|
gastritis, atrophic - metabolism - pathology |
1 |
|
gastro oesophageal reflux, treatment |
1 |
|
gastroduodenal ulcer |
1 |
|
gastroenterologists |
1 |
|
gastroenterology - methods |
1 |
|
gastroenterology - standards |
1 |
|
gastroesophageal reflux - classification |
1 |
|
gastroesophageal reflux - complications - diagnosis - epidemiology |
1 |
|
gastroesophageal reflux - complications - diagnosis - physiopathology |
1 |
|
gastroesophageal reflux - diagnosis - drug therapy |
1 |
|
gastroesophageal reflux - diagnosis - drug therapy - epidemiology |
1 |
|
gastroesophageal reflux - diagnosis - drug therapy - epidemiology - physiopathology - therapy |
1 |
|
gastroesophageal reflux - diagnosis - epidemiology - therapy |
1 |
|
gastroesophageal reflux - diagnosis - etiology - therapy |
1 |
|
gastroesophageal reflux - diagnosis - physiopathology |
1 |
|
gastroesophageal reflux - epidemiology - pathology - physiopathology |
1 |
|
gastroesophageal reflux - etiology |
1 |
|
gastroesophageal reflux - microbiology |
1 |
|
gastrointestinal agents - therapeutic use |
1 |
|
gastrointestinal disease |
1 |
|
gastrointestinal diseases - blood - microbiology - pathology |
1 |
|
gastrointestinal diseases - diagnosis - etiology |
1 |
|
gastrointestinal hemorrhage - drug therapy - physiopathology - ultrasonography |
1 |
|
gastrointestinal hemorrhage - therapy |
1 |
|
gastrointestinal symptoms |
1 |
|
gastroparesis |
1 |
|
gastroscopy |
1 |
|
gastroscopy - methods |
1 |
|
gene expression regulation, enzymologic - drug effects |
1 |
|
gene frequency |
1 |
|
genes, bacterial |
1 |
|
genes, bacterial - genetics |
1 |
|
genes, myc - genetics |
1 |
|
genes, neoplasm - genetics |
1 |
|
genes, p53 - genetics |
1 |
|
genetic polymorphism |
1 |
|
granulation tissue - cytology - drug effects |
1 |
|
great britain - epidemiology |
1 |
|
h. pylori |
1 |
|
h.pylori 感染 |
1 |
|
h2-receptor antagonists |
1 |
|
health attitudes |
1 |
|
health care surveys |
1 |
|
health knowledge, attitudes, practice |
1 |
|
health services accessibility |
1 |
|
heartburn |
1 |
|
heartburn - diagnosis |
1 |
|
heiicobacter pylori |
1 |
|
helicobacter infections |
1 |
|
helicobacter infections - blood - epidemiology - microbiology |
1 |
|
helicobacter infections - complications - diagnosis - drug therapy - epidemiology |
1 |
|
helicobacter infections - complications - diagnosis - epidemiology |
1 |
|
helicobacter infections - complications - drug therapy - epidemiology |
1 |
|
helicobacter infections - complications - drug therapy - prevention & control |
1 |
|
helicobacter infections - complications - pathology |
1 |
|
helicobacter infections - diagnosis - drug therapy |
1 |
|
helicobacter infections - diagnosis - drug therapy - epidemiology |
1 |
|
helicobacter infections - diagnosis - drug therapy - microbiology |
1 |
|
helicobacter infections - diagnosis - epidemiology |
1 |
|
helicobacter infections - diagnosis - etiology |
1 |
|
helicobacter infections - diagnosis - immunology - microbiology |
1 |
|
helicobacter infections - diagnosis - pathology |
1 |
|
helicobacter infections - drug therapy - epidemiology - genetics |
1 |
|
helicobacter infections - drug therapy - epidemiology - microbiology |
1 |
|
helicobacter infections - drug therapy - microbiology - pathology |
1 |
|
helicobacter infections - epidemiology |
1 |
|
helicobacter infections - epidemiology - microbiology |
1 |
|
helicobacter infections - ethnology - genetics |
1 |
|
helicobacter infections - metabolism - microbiology - pathology |
1 |
|
helicobacter infections - metabolism - pathology |
1 |
|
helicobacter infections/therapy |
1 |
|
helicobacter pylori - classification - genetics - isolation & purification |
1 |
|
helicobacter pylori - classification - genetics - pathogenicity |
1 |
|
helicobacter pylori - drug effects - enzymology - genetics - isolation & purification |
1 |
|
helicobacter pylori - drug effects - growth & development |
1 |
|
helicobacter pylori - drug effects - pathogenicity |
1 |
|
helicobacter pylori - genetics - isolation & purification |
1 |
|
helicobacter pylori - genetics - pathogenicity |
1 |
|
helicobacter pylori infection |
1 |
|
hemochromatosis |
1 |
|
hemochromatosis - genetics - pathology |
1 |
|
hemochromatosis gene |
1 |
|
hemodynamics - drug effects |
1 |
|
hemostasis, endoscopic |
1 |
|
hepatic artery - ultrasonography |
1 |
|
hepaticstellate cell |
1 |
|
hepatocytes - chemistry - cytology - drug effects |
1 |
|
hiatal hernia |
1 |
|
histamine h2 antagonists - therapeutic use |
1 |
|
histocompatibility antigens class i - genetics |
1 |
|
histocompatibility antigens class ii - immunology - metabolism |
1 |
|
histology |
1 |
|
histones - metabolism |
1 |
|
hla antigens - genetics |
1 |
|
homeodomain proteins - analysis |
1 |
|
homeoproteins |
1 |
|
hospitalization |
1 |
|
hospitals, university |
1 |
|
hydrocarbons, fluorinated - pharmacology |
1 |
|
hyperplasia |
1 |
|
hyperplasia - metabolism - pathology |
1 |
|
hypersensitivity, delayed |
1 |
|
hypertension, portal - complications - pathology |
1 |
|
icea |
1 |
|
immunocytochemistry |
1 |
|
immunoglobulin g - analysis - immunology |
1 |
|
immunoglobulin g - immunology |
1 |
|
immunohistochemistry - methods |
1 |
|
indicators and reagents |
1 |
|
indoles - therapeutic use |
1 |
|
indometacin |
1 |
|
indomethacin - toxicity |
1 |
|
inflammation - enzymology - prevention & control |
1 |
|
inflammation - metabolism |
1 |
|
inflammatory bowel disease |
1 |
|
inflammatory bowel diseases - chemically induced - enzymology - prevention & control |
1 |
|
intercellular adhesion molecule-1 - immunology - metabolism |
1 |
|
international cooperation |
1 |
|
internationality |
1 |
|
intervention |
1 |
|
intervention study |
1 |
|
intestinal mucosa - microbiology - pathology |
1 |
|
intestinal mucosa - pathology |
1 |
|
intestinal neoplasms - pathology |
1 |
|
intestinal polyps - epidemiology - pathology |
1 |
|
intestinal polyps - pathology |
1 |
|
intestinal polyps - radiography |
1 |
|
intracellular ca2+ |
1 |
|
intramolecular oxidoreductases - immunology - metabolism |
1 |
|
iron |
1 |
|
isoenzymes - antagonists & inhibitors - genetics - metabolism |
1 |
|
isoenzymes - metabolism |
1 |
|
japan |
1 |
|
ki-67 antigen - metabolism |
1 |
|
kinetics |
1 |
|
l-vocc |
1 |
|
leucine - analogs & derivatives - pharmacology |
1 |
|
leukocyte count |
1 |
|
liver cirrhosis - complications - physiopathology - ultrasonography |
1 |
|
liver neoplasms - complications - pathology |
1 |
|
lscm |
1 |
|
lymphoma, b-cell, marginal zone - microbiology - prevention & control |
1 |
|
macrophage migration-inhibitory factors - genetics - immunology - metabolism |
1 |
|
medication adherence |
1 |
|
metaplasia - metabolism - pathology |
1 |
|
metaplasia - parasitology |
1 |
|
methotrexate - pharmacology |
1 |
|
metronidazole - pharmacology |
1 |
|
mice, knockout |
1 |
|
microsatellite repeats - genetics |
1 |
|
microscopy, confocal |
1 |
|
microvilli - pathology |
1 |
|
molecular biology |
1 |
|
monitoring, ambulatory |
1 |
|
montreal classification |
1 |
|
mucus - metabolism - secretion |
1 |
|
multistage tissue |
1 |
|
muscle relaxation |
1 |
|
myocardial infarction - chemically induced |
1 |
|
near patient test |
1 |
|
neovascularization, physiologic - drug effects |
1 |
|
neurons, afferent - drug effects |
1 |
|
neutrophil |
1 |
|
neutrophils - drug effects |
1 |
|
nitric oxide - physiology |
1 |
|
nitroglycerin - therapeutic use |
1 |
|
nitroreductases - genetics - metabolism |
1 |
|
non cardiac chest pain |
1 |
|
non-hfe iron overload |
1 |
|
non-steroidal anti-inflammatory drugs |
1 |
|
nucleic acid synthesis inhibitors - pharmacology |
1 |
|
nutrition |
1 |
|
obesity |
1 |
|
octreotid |
1 |
|
octreotide - pharmacology |
1 |
|
oligopeptides - pharmacology |
1 |
|
omeprazole - analogs & derivatives - diagnostic use - therapeutic use |
1 |
|
oncogene |
1 |
|
oryza sativa |
1 |
|
otolaryngologists |
1 |
|
otolaryngology - methods |
1 |
|
pacific islands |
1 |
|
pacific islands - epidemiology |
1 |
|
paired box transcription factors - analysis |
1 |
|
pakistan |
1 |
|
pancreatitis - complications - diagnosis - therapy |
1 |
|
pathogenesis |
1 |
|
patient discharge - standards - trends |
1 |
|
patient satisfaction |
1 |
|
penicillins - administration & dosage - therapeutic use |
1 |
|
penicillins - adverse effects - therapeutic use |
1 |
|
pentoxifylline - pharmacology |
1 |
|
pepstatins - pharmacology |
1 |
|
peptic ulcer - chemically induced |
1 |
|
peptic ulcer - chemically induced - complications - therapy |
1 |
|
peptic ulcer - complications - drug therapy |
1 |
|
peptic ulcer - etiology |
1 |
|
peptic ulcer hemorrhage - chemically induced - drug therapy |
1 |
|
peptic ulcer hemorrhage - diagnosis - etiology - physiopathology |
1 |
|
peptic ulcer hemorrhage - drug therapy - etiology - pathology |
1 |
|
peptic ulcer hemorrhage - drug therapy - pathology |
1 |
|
peptic ulcer/drug therapy |
1 |
|
peptide fragments - metabolism |
1 |
|
periodicals as topic - statistics & numerical data |
1 |
|
peristalsis |
1 |
|
peroxidase - drug effects - metabolism |
1 |
|
phenanthridines - pharmacology |
1 |
|
phosphodiesterase inhibitors - pharmacology |
1 |
|
physician's practice patterns - statistics & numerical data |
1 |
|
physicians, family |
1 |
|
pkcδ |
1 |
|
polyp detection |
1 |
|
population surveillance - methods |
1 |
|
portal hypertension |
1 |
|
portal system - physiopathology |
1 |
|
portal vein - ultrasonography |
1 |
|
postprandial period |
1 |
|
precancerous conditions - epidemiology - pathology |
1 |
|
premalignant lesions |
1 |
|
prevention |
1 |
|
primary care |
1 |
|
primary care physicians |
1 |
|
primary health care |
1 |
|
prostaglandin |
1 |
|
prostaglandin-endoperoxide synthases - metabolism |
1 |
|
prostaglandins - biosynthesis |
1 |
|
protein kinase c - antagonists & inhibitors - physiology |
1 |
|
protein kinase c - genetics - metabolism |
1 |
|
protein kinase c - metabolism |
1 |
|
protein kinase c - metabolism - physiology |
1 |
|
protein kinase c-delta |
1 |
|
proton pump inhibitor test |
1 |
|
proton pump inhibitors - pharmacology - therapeutic use |
1 |
|
proton pump inhibitors, therapeutic use |
1 |
|
proton pumps - therapeutic use |
1 |
|
public health |
1 |
|
publishing - statistics & numerical data |
1 |
|
pyloric antrum - chemistry - microbiology |
1 |
|
pyloric antrum - microbiology - pathology |
1 |
|
pyrans - pharmacology |
1 |
|
randomized controlled trial |
1 |
|
ranitidine bismuth citrate-triple therapy |
1 |
|
rantitidine bismuth citrate |
1 |
|
rectal neoplasms - pathology |
1 |
|
rectum - pathology |
1 |
|
referral and consultation - standards |
1 |
|
registries - statistics & numerical data |
1 |
|
repressor proteins - analysis |
1 |
|
rescue therapy |
1 |
|
research design - standards |
1 |
|
respiratory function tests |
1 |
|
rna, messenger - biosynthesis - drug effects |
1 |
|
rna, messenger - drug effects - genetics - metabolism |
1 |
|
rottlerin |
1 |
|
salicylates - pharmacology |
1 |
|
salivary glands - drug effects - metabolism |
1 |
|
salt |
1 |
|
secondary care |
1 |
|
selection (genetics) |
1 |
|
sensory nerves |
1 |
|
sequence analysis, dna |
1 |
|
sero-revalence |
1 |
|
seroepidemiologic studies |
1 |
|
serologic tests - methods |
1 |
|
serological proteins |
1 |
|
somatostatin - therapeutic use |
1 |
|
south africa |
1 |
|
south china |
1 |
|
spiro compounds - pharmacology |
1 |
|
stomach |
1 |
|
stomach - chemistry - microbiology - pathology |
1 |
|
stomach - microbiology |
1 |
|
stomach neoplasms |
1 |
|
stomach neoplasms - blood - epidemiology - microbiology |
1 |
|
stomach neoplasms - diagnosis - epidemiology - microbiology |
1 |
|
stomach neoplasms - drug therapy - enzymology |
1 |
|
stomach neoplasms - epidemiology - etiology |
1 |
|
stomach neoplasms - epidemiology - etiology - therapy |
1 |
|
stomach neoplasms - epidemiology - microbiology |
1 |
|
stomach neoplasms - ethnology - pathology - surgery |
1 |
|
stomach neoplasms - etiology - prevention & control |
1 |
|
stomach neoplasms - genetics - microbiology - ultrastructure |
1 |
|
stomach neoplasms - genetics - physiopathology |
1 |
|
stomach neoplasms - microbiology |
1 |
|
stomach neoplasms - microbiology - pathology - prevention & control |
1 |
|
stomach neoplasms - microbiology - prevention & control |
1 |
|
stomach neoplasms - prevention & control |
1 |
|
stomach neoplasms/epidemiology |
1 |
|
stomach ulcer - blood - etiology - prevention & control |
1 |
|
stomach ulcer - complications - drug therapy - microbiology |
1 |
|
stomach ulcer - drug therapy - microbiology - prevention & control |
1 |
|
stomach ulcer - epidemiology - etiology |
1 |
|
stomach ulcer - etiology - immunology - metabolism |
1 |
|
stomach ulcer - etiology - pathology |
1 |
|
stomach ulcer - pathology |
1 |
|
storage temperature |
1 |
|
stroke - chemically induced |
1 |
|
tablets - adverse effects |
1 |
|
taiwan |
1 |
|
test and treat |
1 |
|
th1 cells - cytology - immunology |
1 |
|
tight junction |
1 |
|
tnf-α (tumor necrosis factor- α) |
1 |
|
tobacco smoke pollution - adverse effects |
1 |
|
trans-activators - analysis |
1 |
|
treatment |
1 |
|
treatment failure |
1 |
|
trinitrobenzenesulfonic acid - administration & dosage |
1 |
|
triticum |
1 |
|
tumor necrosis factor-alpha - analysis - metabolism |
1 |
|
tumor necrosis factor-alpha - genetics |
1 |
|
tumor necrosis factor-alpha - immunology - metabolism |
1 |
|
tumor suppressor protein p53 - biosynthesis - physiology |
1 |
|
ulcer healing |
1 |
|
ulcerative colitis |
1 |
|
united states |
1 |
|
united states - epidemiology |
1 |
|
urea - chemistry |
1 |
|
urease |
1 |
|
vaca |
1 |
|
vaccination |
1 |
|
vasoconstrictor agents - therapeutic use |
1 |
|
vasodilator agents - therapeutic use |
1 |
|
virtual colonoscopy |
1 |
|
virulence - genetics |
1 |
|
vital capacity - physiology |
1 |
|
world health |
1 |
|
wound healing |
1 |
|
反流病 |
1 |
|
幽門螺桿菌感染 |
1 |
|
食管炎 |
1 |
